A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3365-3370

  Saito, Hiroki ^a   Ando, Satoshi ^b   Morishita, Naoya ^a   Lee, Kyung Mi ^c   Dator, Dante ^d   Dy, David ^e   Shigemura, Katsumi ^a   Adhim, Zainal ^a   Nibu, Ken Ichi ^a   Fujisawa, Masato ^a   Shirakawa, Toshiro ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c Korea University College of Medicine   (South Korea)

^d National Kidney and Transplant Institute Philippines   (Philippines)

^e ST LUKE S MEDICAL CENTER   (Philippines)

Author keywords

Ad p53 gene therapy; Head neck squamous cell carcinoma; LAK immunotherapy; TNF a

Indexed keywords

ADENOVIRUS VECTOR; BINDING PROTEIN; CD3 ANTIGEN; CD56 ANTIGEN; MESSENGER RNA; PROTEIN P53; PROTEIN UL16 BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; SIGNAL PEPTIDE; TP53 PROTEIN, HUMAN; ULBP1 PROTEIN, HUMAN;

ADENOVIRUS INFECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM SURVIVAL; LYMPHOKINE ACTIVATED KILLER CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AD-P53 GENE THERAPY; ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; GENE THERAPY; GENETICS; HEAD AND NECK TUMOR; HEAD NECK SQUAMOUS CELL CARCINOMA; HYPOPHARYNX TUMOR; IMMUNOLOGY; LAK IMMUNOTHERAPY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; SQUAMOUS CELL CARCINOMA; TNF-A; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

AD-P53 GENE THERAPY; HEAD NECK SQUAMOUS CELL CARCINOMA; LAK IMMUNOTHERAPY; TNF-A;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; GENES, P53; GENETIC THERAPY; GPI-LINKED PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOTHERAPY, ADOPTIVE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, LYMPHOKINE-ACTIVATED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906343606     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Escudier B, Farace F, Angevin E, Charpentier F, Nitenberg G, Triebel F and Hercend T: Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 30A(8): 1078-1083, 1994.
2. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL and DePriest MC: Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 32(9): 914-919, 2009.
3. Savas B, Kerr PE and Pross HF: Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug-resistant breast carcinoma. Cancer Cell Int 6-24, 2006.
4. Swisher SG, Roth JA, Nemunaitis J Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D and Waugh MK: Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 91(9): 763-771, 1999.
5. Clayman GL, Frank DK, Bruso PA and Goepfert H: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5(7): 1715-1722, 1999.
6. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB Jr., Schrump DS, Shin DM, Walsh GL and Roth JA: Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type P53 (Ad-p53). Cancer Gene Ther 7(4): 530-536, 2000.
7. Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B and Lu YY: Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 27: 799-804, 2009.
8. Spear P, Wu MR, Sentman ML and Sentman CL: NKG2D ligands as therapeutic targets. Cancer Immun 13: 8, 2013.
9. Eleme K, Taner SB, Onfelt B, Collinson LM, McCann FE, Chalupny NJ, Cosman D, Hopkins C, Magee AI and Davis DM: Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T-cells via NKG2D. J Exp Med 199: 1005-1010, 2004.
10. Brandstadter JD, Yang Y: Natural killer cell responses to viral infection. J Innate Immun 3(3): 274-279, 2011.
11. Van Dommelen SL and Degli-Esposti MA: NKT cells and viral immunity. Immunol Cell Biol 82(3): 332-341, 2004.
12. Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, Kärre K, Carbone E and Selivanova G: Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell cycle 10: 3346-3358, 2011.
13. Peng Z: Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16(9): 1016-1027, 2005.
14. Rampersad SN: Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel) 12(9): 12347-12360, 2012.
15. Hedlund M, Stenqvist AC, Nagaeva O, Kjellberg L, Wulff M, Baranov V and Mincheva-Nilsson L: Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immuno-suppressive function. J Immunol 183: 340-351, 2009.
16. Zhang L, Hou Y, Zhang J, Hu J and Zhang K: Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett 5: 1826-1832, 2013.
17. Jiang J, Wu C and Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med 11: 83, 2013.
18. Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, Corallo M, Perillo A, Scambia G, Pierelli L and Rutella S: Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinicalgrade cultures. J Transl Med 8: 129, 2010.
19. Mercer JC, Ragin MJ and August A: Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 37: 1337-1343, 2005.
20. Sutlu T and Alici E: Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266: 154-181, 2009.